Related Experiment Videos
[Pulse corticoid therapy in rheumatology].
Presse Medicale (Paris, France : 1983)
|May 12, 1984
Summary
High-dose corticosteroid infusions, like methylprednisolone, show limited, short-term benefits for certain autoimmune diseases. Close monitoring is crucial due to frequent side effects in patients receiving this intensive treatment.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Context:
- High-dose corticosteroid infusions (methylprednisolone 1 g/day for 1-3 days) are a nephrology treatment for acute kidney transplant rejection and severe glomerulonephritis.
- This intensive therapy is increasingly explored for non-renal autoimmune conditions like systemic lupus erythematosus, rheumatoid arthritis, and ankylosing spondylitis.
Purpose:
- To evaluate the efficacy and safety of high-dose methylprednisolone infusions in managing acute episodes of kidney transplant rejection and specific autoimmune diseases.
- To assess the short-term (3-month) improvement and potential adverse effects associated with this high-dose corticosteroid regimen.
Summary:
- Massive methylprednisolone infusions demonstrate variable short-term efficacy in autoimmune diseases, with improvement not universally observed.
- While not directly linked to mortality in transplant patients, significant side effects occur in approximately 50% of cases, necessitating vigilant monitoring of electrolytes and ECGs.
Impact:
- The use of high-dose corticosteroids requires careful patient selection and intensive monitoring due to a high incidence of adverse events.
- Further controlled studies are needed to establish definitive conclusions on the long-term benefits and risks in non-renal autoimmune conditions.